Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein (Monomer, MALS verified)

Customer Reviews
Cat. No. / Size
Price
Availability
Qty
HLE-H82E6-25ug
$125.00
In Stock - Delivery in 2-3 business days
HLE-H82E6-200ug
$700.00
In Stock - Delivery in 2-3 business days

Product Details

  • Synonyms

    HLA-A*0201 & B2M & PRAME (ALYVDSLFFL)

  • Source

    Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein (HLE-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & ALYVDSLFFL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & ALYVDSLFFL).

    Predicted N-terminus: Gly 25 & Ile 21

    Request for sequence
  • Molecular Characterization

    Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein is produced by co-expression of HLA and B2M loaded with PRAME peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    HLA-A*0201 & B2M & PRAME (ALYVDSLFFL) SDS-PAGE

    Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HLA-A*0201 & B2M & PRAME (ALYVDSLFFL) SEC-MALS

    The purity of Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein (Cat. No. HLE-H82E6) is more than 95% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*0201 & B2M & PRAME (ALYVDSLFFL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein (Cat. No. HLE-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  HLA-A*0201 & B2M & PRAME (ALYVDSLFFL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein (Cat. No. HLE-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-PRAME (ALYVDSLFFL) TCR-Like Antibody (Pr20), HLA-A*0201-Restricted with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  HLA-A*0201 & B2M & PRAME (ALYVDSLFFL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Complex Protein (Cat. No. HLE-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


Background

PRAME (Preferentially Expressed Antigen in Melanoma) is a well-characterized member of the cancer/testis antigen family. Functioning as a nuclear receptor and transcriptional regulator, PRAME negatively modulates retinoic acid signaling, thereby regulating tumor cell differentiation and proliferation. It is aberrantly overexpressed in a variety of malignancies, especially cutaneous melanoma, and its upregulation is closely linked to aggressive tumor phenotypes. Given its tumor-specific expression and oncogenic role, PRAME has emerged as a promising diagnostic biomarker, prognostic indicator, and attractive therapeutic target for tumor immunotherapy.

Recent Advances

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • FAQ
  • Background